Loading…

Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled, clinical trial

The aim of this study was to determine the effects of caffeine and chlorogenic acid supplementation on gut microbiota, and metabolic disturbances in patients with NAFLD and diabetes. In this randomized, placebo-controlled, clinical trial, 26 patients with diabetes and NAFLD were randomly assigned to...

Full description

Saved in:
Bibliographic Details
Published in:EXCLI journal 2020-01, Vol.19, p.241-250
Main Authors: Mansour, Asieh, Mohajeri-Tehrani, Mohammad Reza, Karimi, Sara, Sanginabadi, Milad, Poustchi, Hossein, Enayati, Samaneh, Asgarbeik, Saeedeh, Nasrollahzadeh, Javad, Hekmatdoost, Azita
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c312t-85c13c8a46433afd33086e67cb3406b13ef11512c80e906e65e10ac955ebf7543
cites
container_end_page 250
container_issue
container_start_page 241
container_title EXCLI journal
container_volume 19
creator Mansour, Asieh
Mohajeri-Tehrani, Mohammad Reza
Karimi, Sara
Sanginabadi, Milad
Poustchi, Hossein
Enayati, Samaneh
Asgarbeik, Saeedeh
Nasrollahzadeh, Javad
Hekmatdoost, Azita
description The aim of this study was to determine the effects of caffeine and chlorogenic acid supplementation on gut microbiota, and metabolic disturbances in patients with NAFLD and diabetes. In this randomized, placebo-controlled, clinical trial, 26 patients with diabetes and NAFLD were randomly assigned to four groups to receive either 200 mg caffeine plus 200 mg chlorogenic acid (CFCA), or 200 mg caffeine plus 200 mg placebo (starch) (CFPL), or 200 mg chlorogenic acid plus 200 mg placebo (CAPL), or 200 mg placebo plus 200 mg placebo (PLPL) for 12 weeks. After 3 months of supplementation, patients in the intervention groups showed a significant decrease in body weight (CFCA group =-3.69 kg; CFPL group=-0.7kg; CAPL group=-0.43kg; PLPL group=0.26 kg) (p=0.004). Weight reduced significantly more in CFCA group compared to all other three groups (p=0.005 for PLPL; p=0.023 for CAPL; and p=0.031 for CFPL). Although the number of gut Bifidobacteria increased in CFCA group, there were no statistically significant differences within and between the groups in any of bacteria numbers. In conclusion, our study showed that 12 weeks consumption of 200 mg/day caffeine plus 200 mg/day chlorogenic acid is effective in reduction of weight in patients with NAFLD and diabetes which might be at least partially through the rise in gut Bifidobacteria. This pilot study shed a light on the pathway of future clinical trials assessing the effects of coffee consumption in these patients. This trial has been registered at clinicaltrial.gov with registration number of NCT02929901.
doi_str_mv 10.17179/excli2019-2021
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7105939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2387692875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c312t-85c13c8a46433afd33086e67cb3406b13ef11512c80e906e65e10ac955ebf7543</originalsourceid><addsrcrecordid>eNpVUc1rFzEQDaLYDz17kzl6cDUfv2x2PQilWBUKPVTPSzY7218km1mTbLX9u_oHGrRKhYF5zHu8x2MYeyH4G2GE6d_iTxe85KJvJJfiETsUrRCNFLp9_AAfsKOcv3GuO67NU3agpNStNPyQ3V3uKRUomBbAeUZXMtAMjirGupaVIsZ6dBTztqzFU4Q6V1uBxbtEo6diwUdYbfG_lT982UOk2NjgaE_BO5htKTcQ_DUmsHGCydsRC-Z3cAKrD1Qg1TMt_hYnWIN1OFJTE0uiEHB6DbVk9M4GKMnb8Iw9mW3I-Px-H7OvZx--nH5qzi8-fj49OW-cErI0nXZCuc7u2p1Sdp6U4l2LrXGj2vF2FApnIbSQruPY88poFNy6XmscZ6N36pi9_-O7buOCk6v1kg3Dmvxi081A1g__M9Hvhyu6Hozguld9NXh1b5Do-4a5DIvPDkOwEWnLg1SdaXvZGV2lLx9m_Qv5-yr1C9synA4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2387692875</pqid></control><display><type>article</type><title>Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled, clinical trial</title><source>PubMed Central</source><creator>Mansour, Asieh ; Mohajeri-Tehrani, Mohammad Reza ; Karimi, Sara ; Sanginabadi, Milad ; Poustchi, Hossein ; Enayati, Samaneh ; Asgarbeik, Saeedeh ; Nasrollahzadeh, Javad ; Hekmatdoost, Azita</creator><creatorcontrib>Mansour, Asieh ; Mohajeri-Tehrani, Mohammad Reza ; Karimi, Sara ; Sanginabadi, Milad ; Poustchi, Hossein ; Enayati, Samaneh ; Asgarbeik, Saeedeh ; Nasrollahzadeh, Javad ; Hekmatdoost, Azita</creatorcontrib><description>The aim of this study was to determine the effects of caffeine and chlorogenic acid supplementation on gut microbiota, and metabolic disturbances in patients with NAFLD and diabetes. In this randomized, placebo-controlled, clinical trial, 26 patients with diabetes and NAFLD were randomly assigned to four groups to receive either 200 mg caffeine plus 200 mg chlorogenic acid (CFCA), or 200 mg caffeine plus 200 mg placebo (starch) (CFPL), or 200 mg chlorogenic acid plus 200 mg placebo (CAPL), or 200 mg placebo plus 200 mg placebo (PLPL) for 12 weeks. After 3 months of supplementation, patients in the intervention groups showed a significant decrease in body weight (CFCA group =-3.69 kg; CFPL group=-0.7kg; CAPL group=-0.43kg; PLPL group=0.26 kg) (p=0.004). Weight reduced significantly more in CFCA group compared to all other three groups (p=0.005 for PLPL; p=0.023 for CAPL; and p=0.031 for CFPL). Although the number of gut Bifidobacteria increased in CFCA group, there were no statistically significant differences within and between the groups in any of bacteria numbers. In conclusion, our study showed that 12 weeks consumption of 200 mg/day caffeine plus 200 mg/day chlorogenic acid is effective in reduction of weight in patients with NAFLD and diabetes which might be at least partially through the rise in gut Bifidobacteria. This pilot study shed a light on the pathway of future clinical trials assessing the effects of coffee consumption in these patients. This trial has been registered at clinicaltrial.gov with registration number of NCT02929901.</description><identifier>ISSN: 1611-2156</identifier><identifier>EISSN: 1611-2156</identifier><identifier>DOI: 10.17179/excli2019-2021</identifier><identifier>PMID: 32256270</identifier><language>eng</language><publisher>Germany: Leibniz Research Centre for Working Environment and Human Factors</publisher><subject>Original</subject><ispartof>EXCLI journal, 2020-01, Vol.19, p.241-250</ispartof><rights>Copyright © 2020 Mansour et al.</rights><rights>Copyright © 2020 Mansour et al. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c312t-85c13c8a46433afd33086e67cb3406b13ef11512c80e906e65e10ac955ebf7543</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105939/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105939/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32256270$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mansour, Asieh</creatorcontrib><creatorcontrib>Mohajeri-Tehrani, Mohammad Reza</creatorcontrib><creatorcontrib>Karimi, Sara</creatorcontrib><creatorcontrib>Sanginabadi, Milad</creatorcontrib><creatorcontrib>Poustchi, Hossein</creatorcontrib><creatorcontrib>Enayati, Samaneh</creatorcontrib><creatorcontrib>Asgarbeik, Saeedeh</creatorcontrib><creatorcontrib>Nasrollahzadeh, Javad</creatorcontrib><creatorcontrib>Hekmatdoost, Azita</creatorcontrib><title>Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled, clinical trial</title><title>EXCLI journal</title><addtitle>EXCLI J</addtitle><description>The aim of this study was to determine the effects of caffeine and chlorogenic acid supplementation on gut microbiota, and metabolic disturbances in patients with NAFLD and diabetes. In this randomized, placebo-controlled, clinical trial, 26 patients with diabetes and NAFLD were randomly assigned to four groups to receive either 200 mg caffeine plus 200 mg chlorogenic acid (CFCA), or 200 mg caffeine plus 200 mg placebo (starch) (CFPL), or 200 mg chlorogenic acid plus 200 mg placebo (CAPL), or 200 mg placebo plus 200 mg placebo (PLPL) for 12 weeks. After 3 months of supplementation, patients in the intervention groups showed a significant decrease in body weight (CFCA group =-3.69 kg; CFPL group=-0.7kg; CAPL group=-0.43kg; PLPL group=0.26 kg) (p=0.004). Weight reduced significantly more in CFCA group compared to all other three groups (p=0.005 for PLPL; p=0.023 for CAPL; and p=0.031 for CFPL). Although the number of gut Bifidobacteria increased in CFCA group, there were no statistically significant differences within and between the groups in any of bacteria numbers. In conclusion, our study showed that 12 weeks consumption of 200 mg/day caffeine plus 200 mg/day chlorogenic acid is effective in reduction of weight in patients with NAFLD and diabetes which might be at least partially through the rise in gut Bifidobacteria. This pilot study shed a light on the pathway of future clinical trials assessing the effects of coffee consumption in these patients. This trial has been registered at clinicaltrial.gov with registration number of NCT02929901.</description><subject>Original</subject><issn>1611-2156</issn><issn>1611-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUc1rFzEQDaLYDz17kzl6cDUfv2x2PQilWBUKPVTPSzY7218km1mTbLX9u_oHGrRKhYF5zHu8x2MYeyH4G2GE6d_iTxe85KJvJJfiETsUrRCNFLp9_AAfsKOcv3GuO67NU3agpNStNPyQ3V3uKRUomBbAeUZXMtAMjirGupaVIsZ6dBTztqzFU4Q6V1uBxbtEo6diwUdYbfG_lT982UOk2NjgaE_BO5htKTcQ_DUmsHGCydsRC-Z3cAKrD1Qg1TMt_hYnWIN1OFJTE0uiEHB6DbVk9M4GKMnb8Iw9mW3I-Px-H7OvZx--nH5qzi8-fj49OW-cErI0nXZCuc7u2p1Sdp6U4l2LrXGj2vF2FApnIbSQruPY88poFNy6XmscZ6N36pi9_-O7buOCk6v1kg3Dmvxi081A1g__M9Hvhyu6Hozguld9NXh1b5Do-4a5DIvPDkOwEWnLg1SdaXvZGV2lLx9m_Qv5-yr1C9synA4</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Mansour, Asieh</creator><creator>Mohajeri-Tehrani, Mohammad Reza</creator><creator>Karimi, Sara</creator><creator>Sanginabadi, Milad</creator><creator>Poustchi, Hossein</creator><creator>Enayati, Samaneh</creator><creator>Asgarbeik, Saeedeh</creator><creator>Nasrollahzadeh, Javad</creator><creator>Hekmatdoost, Azita</creator><general>Leibniz Research Centre for Working Environment and Human Factors</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled, clinical trial</title><author>Mansour, Asieh ; Mohajeri-Tehrani, Mohammad Reza ; Karimi, Sara ; Sanginabadi, Milad ; Poustchi, Hossein ; Enayati, Samaneh ; Asgarbeik, Saeedeh ; Nasrollahzadeh, Javad ; Hekmatdoost, Azita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c312t-85c13c8a46433afd33086e67cb3406b13ef11512c80e906e65e10ac955ebf7543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mansour, Asieh</creatorcontrib><creatorcontrib>Mohajeri-Tehrani, Mohammad Reza</creatorcontrib><creatorcontrib>Karimi, Sara</creatorcontrib><creatorcontrib>Sanginabadi, Milad</creatorcontrib><creatorcontrib>Poustchi, Hossein</creatorcontrib><creatorcontrib>Enayati, Samaneh</creatorcontrib><creatorcontrib>Asgarbeik, Saeedeh</creatorcontrib><creatorcontrib>Nasrollahzadeh, Javad</creatorcontrib><creatorcontrib>Hekmatdoost, Azita</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>EXCLI journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mansour, Asieh</au><au>Mohajeri-Tehrani, Mohammad Reza</au><au>Karimi, Sara</au><au>Sanginabadi, Milad</au><au>Poustchi, Hossein</au><au>Enayati, Samaneh</au><au>Asgarbeik, Saeedeh</au><au>Nasrollahzadeh, Javad</au><au>Hekmatdoost, Azita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled, clinical trial</atitle><jtitle>EXCLI journal</jtitle><addtitle>EXCLI J</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>19</volume><spage>241</spage><epage>250</epage><pages>241-250</pages><issn>1611-2156</issn><eissn>1611-2156</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The aim of this study was to determine the effects of caffeine and chlorogenic acid supplementation on gut microbiota, and metabolic disturbances in patients with NAFLD and diabetes. In this randomized, placebo-controlled, clinical trial, 26 patients with diabetes and NAFLD were randomly assigned to four groups to receive either 200 mg caffeine plus 200 mg chlorogenic acid (CFCA), or 200 mg caffeine plus 200 mg placebo (starch) (CFPL), or 200 mg chlorogenic acid plus 200 mg placebo (CAPL), or 200 mg placebo plus 200 mg placebo (PLPL) for 12 weeks. After 3 months of supplementation, patients in the intervention groups showed a significant decrease in body weight (CFCA group =-3.69 kg; CFPL group=-0.7kg; CAPL group=-0.43kg; PLPL group=0.26 kg) (p=0.004). Weight reduced significantly more in CFCA group compared to all other three groups (p=0.005 for PLPL; p=0.023 for CAPL; and p=0.031 for CFPL). Although the number of gut Bifidobacteria increased in CFCA group, there were no statistically significant differences within and between the groups in any of bacteria numbers. In conclusion, our study showed that 12 weeks consumption of 200 mg/day caffeine plus 200 mg/day chlorogenic acid is effective in reduction of weight in patients with NAFLD and diabetes which might be at least partially through the rise in gut Bifidobacteria. This pilot study shed a light on the pathway of future clinical trials assessing the effects of coffee consumption in these patients. This trial has been registered at clinicaltrial.gov with registration number of NCT02929901.</abstract><cop>Germany</cop><pub>Leibniz Research Centre for Working Environment and Human Factors</pub><pmid>32256270</pmid><doi>10.17179/excli2019-2021</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1611-2156
ispartof EXCLI journal, 2020-01, Vol.19, p.241-250
issn 1611-2156
1611-2156
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7105939
source PubMed Central
subjects Original
title Short term effects of coffee components consumption on gut microbiota in patients with non-alcoholic fatty liver and diabetes: A pilot randomized placebo-controlled, clinical trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T20%3A20%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%20term%20effects%20of%20coffee%20components%20consumption%20on%20gut%20microbiota%20in%20patients%20with%20non-alcoholic%20fatty%20liver%20and%20diabetes:%20A%20pilot%20randomized%20placebo-controlled,%20clinical%20trial&rft.jtitle=EXCLI%20journal&rft.au=Mansour,%20Asieh&rft.date=2020-01-01&rft.volume=19&rft.spage=241&rft.epage=250&rft.pages=241-250&rft.issn=1611-2156&rft.eissn=1611-2156&rft_id=info:doi/10.17179/excli2019-2021&rft_dat=%3Cproquest_pubme%3E2387692875%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c312t-85c13c8a46433afd33086e67cb3406b13ef11512c80e906e65e10ac955ebf7543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2387692875&rft_id=info:pmid/32256270&rfr_iscdi=true